Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1996-07-12
1999-12-28
Fonda, Kathleen K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 25, 514 54, A61K 31715, A61K 3170
Patent
active
060082038
ABSTRACT:
The present invention discloses carbohydrates and carbohydrate analogs that bind to epidermal growth factor (EGF) receptors. Methods of using such carbohydrates or analogs for a variety of uses related to the EGF receptor are also provided. In preferred aspects of the present invention, methods for killing or inhibiting the growth of tumor cells with increased EGF receptor activity are disclosed.
REFERENCES:
patent: 3336155 (1967-08-01), Rowe
patent: 4224179 (1980-09-01), Schneider
patent: 4241046 (1980-12-01), Papahadjopoulos et al.
patent: 5034516 (1991-07-01), Roy et al.
patent: 5401723 (1995-03-01), Gaffar et al.
patent: 5470829 (1995-11-01), Prisell et al.
Carlsson et al. Int. J. Radiat. Oncol. Biol. Phys. 1994, 30(1), 105-115. Month not available.
Bremer, Eric, "Glycosphingolipids as Effectors of Growth and Differentiation," Current Topics in Membranes 40: 387-411, Feb. 1994.
Yednak and Bremer, "Preferential Binding of the Epidermal Growth Factor Receptor to Ganglioside GM3 Coated Plates," Molecular and Chemical Neuropathology 21:369-378, 1994.
Bremer et al., "Ganglioside-mediated Modulation of Cell Growth. Specific Effects of G.sub.M3 on Tyrosine Phosphorylation of the Epidermal Growth Factor Receptor," Journal of Biological Chemistry 261(5): 2434-2440, 1986.
Hattori et al., "Sialyllactose-mediated Cell Interaction during Granulosa Cell Differentiation. Identification of Its Binding Proteins," Journal of Biological Chemistry 270(14): 7858-7863, Apr. 1995.
Hanai et al., "Ganglioside-mediated Modulation of Cell Growth. Specific Effects of GM.sub.3 Lyso-GM.sub.3 in Tyrosine Phosphorylation of the Epidermal Growth Factor Receptor," Journal of Biological Chemistry 263(22): 10915-10921, Aug. 1988.
Aasland et al., "Expression of oncogenes in thyroid tumours: Coexpression of c-erbB2
eu and c-erbB," Br. J. Cancer 57: 358-363, 1988.
Aruffo et al., "CD44 Is the Principal Cell Surface Receptor for Hyaluronate," Cell 61: 1303-1313, Jun. 1990.
Arvidsson et al., "Tyr-716 in the Platelet-Derived Growth Factor .beta.-Receptor Kinase Insert Is Involved in GRB2 Binding as Ras Activation," Molecular and Cellular Biology 14(10): 6715-6726, Oct. 1994.
Carpenter, G., "Receptors for Epidermal Growth Factor And Other Polypeptide Mitogens," Ann. Rev. Biochem. 56: 881-914, 1987.
Downward et al., "Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences," Nature 307: 521-527, Feb. 1984.
Glenney et al., "Monoclonal antibodies to phosphotyrosine," Journal of Immunological Methods 109: 277-285, 1988.
Kijima-Suda et al., "Possible Mechanism of Inhibition of Experimental Pulmonary Metastasis of Mouse colon Adenocarcinoma 26 Sublines by a Sialic Acid: Nucleoside Conjugate," Cancer Research 48(13): 3728-3732, 1988.
Kim, S., "Liposomes as Carriers of Cancer Chemotherapy. Current Status and Future Prospects," Drugs 46(4): 618-638, 1993.
King et al., "High Throughput Assay for Inhibitors of the Epidermal Growth Factor Receptor-Associated Tyrosine Kinase," Life Sciences 53: 1465-1472, 1993.
Libermann et al., "Amplification and Overexpression of the EGF Receptor Gene in Primary Human Glioblastomas," J. Cell Sci. (Suppl. 3): 161-172, 1985.
Lu et al., "Amplification of the EGF Receptor and c-myc Genes in Human Esophageal Cancers," Int. J. Cancer 42: 502-505, 1988.
Peteron, G., "A Simplification of the Protein Assay Method of Lowry et al. Which is More Generally Applicable," Analytical Biochemistry 83: 346-356, 1977.
Pike et al., "Epidermal growth factor stimulates the phosphorylation of synthetic tyrosine-containing peptides by A431 cell membranes," Proc. Natl. Acad. Sci. USA 79: 1443-1447, Mar. 1982.
Rowlinson-Busza and Epenetos, "Targeted delivery of biologic and other antineoplastic agents," Current Opinion in Oncology 4: 1142-1148, Dec. 1992.
Schauer et al., "The Anti-Recognition Function of Sialic Acids: Studies with Erythrocytes and Macrophages," Pure & Appl. Chem. 56(7): 907-921, 1984.
Sugarman and Perez-Soler, "Liposomes in the treatment of malignancy: A clinical perspective," Critical Reviews in Oncology/Hematology 12(3): 231-242, 1992.
Tokovenko et al., "Inhibition of Mycoplasma Pneumoniae Adhesion in the Fetuinic Test System By Synthetic Analogues and Polymeric Forms of Neuraminic Acids," Mikrobiologichny Zhurnal 56(1): 3-9, 1994.
Yarden et al., "Purification of an Active EGF Receptor Kinase with Monoclonal Antireceptor Antibodies," Journal Biological Chemistry 260: 315-319, Jan. 1985.
Patent Abstracts of Japan, JP 63 063972, abstract date Aug. 8, 1988, patent date Mar. 22, 1988.
Bremer Eric G.
Magnani John L.
Fonda Kathleen K.
GlycoTech Corp.
LandOfFree
Methods for treatment of EGF receptor associated cancers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treatment of EGF receptor associated cancers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treatment of EGF receptor associated cancers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2382495